Danielle antalffy
WebAug 6, 2024 · Danielle Antalffy-- SVB Leerink -- Analyst. Thank you. Operator. Your next question is from the line of Chad Messer with Needham & Company. Chad Messer-- Needham and Company -- Analyst. Great. Thanks. WebMay 15, 2024 · Danielle Antalffy - SVB Securities Operator Good day, and thank you for standing by. Welcome to the Minerva Surgical First Quarter 2024 Earnings Call. At this …
Danielle antalffy
Did you know?
WebFirst, we’ll talk with Danielle Antalffy, managing director at SVB Leerink. Antalffy covers most of the major medtechs but we’ll focus on a new report she issues on sugaring home … WebJan 11, 2024 · 1 Abbott Laboratories## ABT Market Perform Danielle Antalffy Medical Supplies and Devices 2 3 ABIOMED, Inc. ABMD Outperform Danielle Antalffy Medical Supplies and Devices 4 AC Immune SA#~~ ACIU Outperform Marc Goodman Biopharma / Neuroscience Dec 10.86 (CHF 0.46) (CHF 0.81) (CHF 0.99) (0.52) NA NA 67.4 732 5
WebMar 22, 2024 · Danielle Antalffy, an SVB Leerink analyst, said that there are about 11 new major products expected to be launched in 2024 into new and/or high-growth markets, likening a new, major product to last year's Abbott Laboratories' Amulet cardiac device. WebUBS analyst Danielle Antalffy recently initiated coverage on InMode with a Buy rating and announced a price target of $40. Stephen Weissof Short Hills Capital Partners said he likes Bunge...
WebMar 30, 2024 · Analist Danielle Antalffy, vermiş olduğu “SAT” notunu, Medtronic (MDT)’in sürdürülebilir orta tek haneli gelir artışına geri dönebilme ve orta vadede istikrarlı bir işletme marjına ulaşabilme olasılıklarına dair belirsizliklere dayandırıyor. WebNov 13, 2024 · Leerink Partner analyst Danielle Antalffy said that they expected that results from the trial might end up having a positive effect on the company’s shares, according to a letter to investors.
WebApr 17, 2024 · Antalffy also cited the biventricular pacing coverage as a positive for the company, adding that the proposal’s coverage of transfer from an outlying hospital valdiate’s Abiomed’s “hub-and-spoke”...
WebDowngrading MDT to Sell from Buy with a $79 target, the analyst Danielle Antalffy projected 2% below consensus sales and 3%/8% below consensus EPS for the company in FY24 and FY25. of the greatest possible degreeWebApr 9, 2024 · Danielle Antalffy UBS Wall Street Analyst #1,991 out of 8,374 Wall Street Analysts #4,507 out of 32,455 experts Success Rate 51% 198 out of 388 transactions … of the grand upwelling wowWebDanielle Antalffy SVB Securities Success Rate 9/24 ratings generated profit 38% Average Return -14.75% assigned a buy rating 11 months ago Copying Danielle Antalffy 's trades and holding each position for 1 Year would result in +37.50% of your transactions generating a profit, with an average return of -14.75% per trade. 2 Years XXXXXXXX XXXX my friend spaceWebOct 27, 2024 · During Boston Scientific's third-quarter earnings call Wednesday, Danielle Antalffy, a senior research analyst covering medtech at SVB Leerink, asked CEO Mike Mahoney about the hospital labor shortages. of the goodness of god lyricsWebItaliano. Français. My Account of the greatest degree crossword clueWebFeb 8, 2024 · In a sector note on U.S. Medical Supplies and Devices, UBS analyst Danielle Antalffy initiated coverage of Inspire Medical with a Buy rating and $300 price target. UBS believes Inspire Medical can drive sustainable 20%+ sales growth in both 2024 and 2024, driven solely by existing indications and geographies, the analyst tells investors in a ... of the governedWebView Danielle Antalffy's record in New York, NY including current phone number, address, relatives, background check report, and property record with Whitepages. ... of the greatest intensity crossword clue